Sripadh Sharma1, Igal Ifergan2, Jonathan E Kurz3, Robert A Linsenmeier4,5, Dan Xu2, John G Cooper1, Stephen D Miller2, John A Kessler1. 1. Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago. 2. Department of Microbiology-Immunology and Interdepartmental Immunobiology Center, Northwestern University Feinberg School of Medicine, Chicago. 3. Davee Pediatric Neurocritical Care Program, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago. 4. Department of Biomedical Engineering, Northwestern University, Evanston, IL. 5. Department of Neurobiology, Northwestern University, Evanston, IL.
Abstract
OBJECTIVE: There are currently no definitive disease-modifying therapies for traumatic brain injury (TBI). In this study, we present a strong therapeutic candidate for TBI, immunomodulatory nanoparticles (IMPs), which ablate a specific subset of hematogenous monocytes (hMos). We hypothesized that prevention of infiltration of these cells into brain acutely after TBI would attenuate secondary damage and preserve anatomic and neurologic function. METHODS: IMPs, composed of US Food and Drug Administration-approved 500nm carboxylated-poly(lactic-co-glycolic) acid, were infused intravenously into wild-type C57BL/6 mice following 2 different models of experimental TBI, controlled cortical impact (CCI), and closed head injury (CHI). RESULTS: IMP administration resulted in remarkable preservation of both tissue and neurological function in both CCI and CHI TBI models in mice. After acute treatment, there was a reduction in the number of immune cells infiltrating into the brain, mitigation of the inflammatory status of the infiltrating cells, improved electrophysiologic visual function, improved long-term motor behavior, reduced edema formation as assessed by magnetic resonance imaging, and reduced lesion volumes on anatomic examination. INTERPRETATION: Our findings suggest that IMPs are a clinically translatable acute intervention for TBI with a well-defined mechanism of action and beneficial anatomic and physiologic preservation and recovery. Ann Neurol 2020;87:442-455.
OBJECTIVE: There are currently no definitive disease-modifying therapies for traumatic brain injury (TBI). In this study, we present a strong therapeutic candidate for TBI, immunomodulatory nanoparticles (IMPs), which ablate a specific subset of hematogenous monocytes (hMos). We hypothesized that prevention of infiltration of these cells into brain acutely after TBI would attenuate secondary damage and preserve anatomic and neurologic function. METHODS: IMPs, composed of US Food and Drug Administration-approved 500nm carboxylated-poly(lactic-co-glycolic) acid, were infused intravenously into wild-type C57BL/6 mice following 2 different models of experimental TBI, controlled cortical impact (CCI), and closed head injury (CHI). RESULTS:IMP administration resulted in remarkable preservation of both tissue and neurological function in both CCI and CHI TBI models in mice. After acute treatment, there was a reduction in the number of immune cells infiltrating into the brain, mitigation of the inflammatory status of the infiltrating cells, improved electrophysiologic visual function, improved long-term motor behavior, reduced edema formation as assessed by magnetic resonance imaging, and reduced lesion volumes on anatomic examination. INTERPRETATION: Our findings suggest that IMPs are a clinically translatable acute intervention for TBI with a well-defined mechanism of action and beneficial anatomic and physiologic preservation and recovery. Ann Neurol 2020;87:442-455.
Authors: Michael J Kane; Mariana Angoa-Pérez; Denise I Briggs; David C Viano; Christian W Kreipke; Donald M Kuhn Journal: J Neurosci Methods Date: 2011-09-12 Impact factor: 2.390
Authors: Fanie Barnabé-Heider; Christian Göritz; Hanna Sabelström; Hirohide Takebayashi; Frank W Pfrieger; Konstantinos Meletis; Jonas Frisén Journal: Cell Stem Cell Date: 2010-10-08 Impact factor: 24.633
Authors: Olena Y Glushakova; Alexander V Glushakov; Likun Yang; Ronald L Hayes; Alex B Valadka Journal: J Neurotrauma Date: 2019-02-25 Impact factor: 5.269
Authors: Hadijat M Makinde; Talia B Just; Carla M Cuda; Nicola Bertolino; Daniele Procissi; Steven J Schwulst Journal: PLoS One Date: 2018-11-01 Impact factor: 3.240
Authors: Yining Zhang; Kevin R Hughes; Ravi M Raghani; Jeffrey Ma; Sophia Orbach; Jacqueline S Jeruss; Lonnie D Shea Journal: Biomaterials Date: 2021-01-08 Impact factor: 12.479
Authors: Laxminarasimha Donthireddy; Prashanthi Vonteddu; Tushar Murthy; Taekyoung Kwak; Rukiye-Nazan Eraslan; Joseph R Podojil; Adam Elhofy; Michael T Boyne; John J Puisis; Filippo Veglia; Surya S Singh; Farokh Dotiwala; Luis J Montaner; Dmitry I Gabrilovich Journal: J Cancer Date: 2022-03-28 Impact factor: 4.207
Authors: Haley E Titus; Yanan Chen; Joseph R Podojil; Andrew P Robinson; Roumen Balabanov; Brian Popko; Stephen D Miller Journal: Front Cell Neurosci Date: 2020-10-27 Impact factor: 5.505